0
0
April 27, 2025 | Silver Spring, Maryland – In a significant stride toward combating some of the world’s most lethal viruses, researchers at the Walter Reed Army Institute of Research have published new findings on the development of vaccines targeting filoviruses – the viral family that includes Ebola and Marburg viruses. Despite decades of study since their discovery, these viruses continue to pose a grave threat due to their high fatality rates and sporadic outbreaks.
Filoviruses are negative single-stranded RNA viruses responsible for severe hemorrhagic fevers with mortality rates reaching as high as 88% in some Marburg virus outbreaks. These viruses typically originate from zoonotic transmission, jumping from fruit bats and other wildlife to humans, often through hunting and butchering bushmeat.
Current Vaccine Landscape and Research Focus
To date, only two vaccines have been approved to prevent Ebola virus infections: Merck’s Ervebo and Janssen Pharmaceuticals’ two-dose Zabdeno and Mvabea regimen. However, no approved vaccines exist for other filoviruses such as the Marburg virus or Sudan virus. The Walter Reed team sought to determine whether the Janssen Ebola vaccine, which includes components targeting multiple filoviruses, could provide cross-protection against other deadly relatives of Ebola.
In a clinical study involving 583 volunteers from Kenya, Mozambique, Nigeria, Tanzania, Uganda, and the United States, participants received the two-dose vaccine either in the standard order (Zabdeno followed by Mvabea) or in reverse. The second dose contains glycoproteins from Ebola, Sudan, and Marburg viruses, as well as the nucleoprotein from the Tai Forest virus, aiming to elicit a broader immune response.
Key Findings: Species-Specific Protection, Need for Multivalent Vaccines
Analysis of blood samples revealed that while the vaccine induced strong antibody responses against Ebola virus, it did not elicit significant cross-reactive immunity to other filoviruses. Similarly, blood from survivors of a Bundibugyo virus outbreak showed limited antibody activity against other filoviruses.
Dr. Thembi Mdluli, lead author and computational biologist, explained, “Our results underscore the vaccine’s potential to provide strong, species-specific protection against Ebola virus while highlighting the critical need for developing multivalent vaccines that can offer broader coverage against other filoviruses.”
Parallel Advances in Antiviral Treatments
Complementing vaccine research, virologists at the University of Texas Medical Branch in Galveston are testing obeldesivir, an oral antiviral pill derived from Remdesivir, which has shown promising results in curing Ebola-infected Rhesus macaques. This development could offer a practical therapeutic option to control outbreaks alongside vaccination efforts.
The Path Ahead
Filoviruses have circulated for thousands of years but only emerged as recognized human pathogens in the 20th century. The 2014–2016 West African Ebola outbreak accelerated vaccine development, culminating in the approval of Ervebo in 2019. However, the absence of vaccines for other filoviruses like Marburg remains a critical gap.
The Walter Reed study, published in Science Translational Medicine, provides valuable insights that will guide future vaccine design toward a multivalent approach capable of protecting against multiple filoviruses, potentially transforming global outbreak preparedness and response.
Disclaimer
This article summarizes research findings as reported by the Walter Reed Army Institute of Research and affiliated institutions. The information is intended for educational and informational purposes only and should not be construed as medical advice. Vaccine development is ongoing, and no broad-spectrum filovirus vaccine is currently approved for general use. For personal health concerns or vaccination guidance, please consult qualified healthcare professionals.
Citations:
